Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder

Bibliography

• KARNO M, GOLDING JM: Obsessive-compulsive disorder. In: Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. Robins LN, Regier DA (Eds), Free Press, New York, USA (1991).
   Google Scholar
• CRINO R, SLADE T, ANDREWS G: The changing prevalence and severity of obsessive-compulsive disorder criteria from DSM-III to DSM-IV. Am. J. Psychiatry. (2005) 162(5):876–82.
   PubMed Web of Science ®Google Scholar
• KORAN LM: Quality of life in obsessive-compulsive disorder. Psych. Clin. North. Am. (2000) 23(3):609–617.
   Web of Science ®Google Scholar
• KORAN LM, THIENEMANN ML, DAVENPORT R: Quality of life for patients with obsessive-compulsive disorder. Am. J. Psychiatry (1996) 153(6):783–788.
   PubMed Web of Science ®Google Scholar
• HOLLANDER E, STEIN D, KWON JH et al.: Psychosocial function and economic costs of obsessive-compulsive disorder. CNS Spectrums (1997) 2:16.
   Google Scholar
• CALVOCORESSI L, LEWIS B, HARRIS M et al.: Family accomodation in obsessive-compulsive disorder. Am. J. Psychiatry (1995) 152(3):441.
   PubMed Web of Science ®Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC, USA (1994).
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. American Psychiatric Association, Washington, DC, USA (2000).
   Google Scholar
• DENYS D, BURGER H, VAN MEGEN H et al.: A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int. Clin. Psychopharmacol (2003) 18:315–322.
   Google Scholar
• RAW KISHORE V, SAIVIAR R, JANARDHAN R et al.: Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder. Eur. Psychiatry (2004) 19:202–208.
   PubMed Web of Science ®Google Scholar
• EISEN JL, RASMUSSEN SA, PHILLIPS KA et al.: Insight and treatment outcome in obsessive-compulsive disorder. Compr. Psychiatry (2001) 42:494–497.
   PubMed Web of Science ®Google Scholar
• FOA EB: Failure in treating obsessive-compulsives. Behav. Res. Ther. (1979) 17(3):169–76.
   PubMed Web of Science ®Google Scholar
• TOFFELSON GD, RAMPEY AH JR, POTVIN JR et al.: A multicenter investigation of fixed dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry (1994) 51:559–567.
   PubMed Web of Science ®Google Scholar
• ZOHAR J, JUDGE R: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br. J. Psychiatry (1996) 169(4):468–474.
   PubMed Web of Science ®Google Scholar
• BISSERBE JC, LANE RM, FLAMENT M et al.: A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur. Psychiatry (1997) 12(2):82–97.
   PubMed Web of Science ®Google Scholar
• KOPONEM H, LEPOLA H, LEINONEN E: Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr. Scand. (1997) 96:343–346.
   PubMed Web of Science ®Google Scholar
• ZOHAR J, INSEL TR, ZOHAR-KADOUCH RC et al: Serotonergic responsivity in obsessive-compulsive disorder. Effect of chronic clomipramine treatment. Arch. Gen. Psychiatry (1988) 45:167–172.
   PubMed Web of Science ®Google Scholar
• GOODMAN WK, PRICE LH, DELGADO PL et al.: Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry (1990) 47:577–585.
   PubMed Web of Science ®Google Scholar
• INSEL TR, MUELLER EA, ALTERMAN I et al.: Obsessive-compulsive disorder and serotonin: is there a connection? Biol. Psychiatry (1985) 20:1174–1188.
   Google Scholar
• FERNANDEZ CE, LOPEZ -IBOR JJ: Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso Esp. Neurol. Psiquiatr. Cienc. Afines (1967) 26:119–147.
   Google Scholar
• RENYNGHE DE VOXRIE GV: Anafranil (G-34586) in obsessive neurosis. Acta NeuroL Belg. (1968) 68:787–792.
   Google Scholar
• ANANTH J: Clomipramine: an antiobsessive drug. Can. J. Psychiatry (1986) 31:253–258.
   PubMed Web of Science ®Google Scholar
• LNSEL TR: New Findings in Obsessive-Compulsive Disorder. American Psychiatric Press, Washington, DC (1984).
   Google Scholar
• LEONARD H, SWEDO S, RAPAPORT JL et aL: Treatment of childhood obsessive-compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacol. Bull. (1988) 24:93–95.
   PubMed Web of Science ®Google Scholar
• THOREN P, ASBERG M, CRONHOLM B et al.: Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch. Gen. Psychiatry (1980) 37:1281–1285.
   PubMed Web of Science ®Google Scholar
• ASBERG M, THOREN P, BERTILSSON L: Clomipramine treatment of obsessive disorder: biochemical and clinical aspects. Psychopharmacol Bull. (1981) 18:13–21.
   Google Scholar
• CLOMIPRAMINE COLLABORATIVE STUDY GROUP: Efficacy of clomipramine in OCD: results of a multicenter double-blind trial. Arch. Gen. Psychiatry (1991) 48:730–738.
   PubMed Web of Science ®Google Scholar
• DEVEAUGH-GEISS J, LANDAU P, KATZ R: Treatment of obsessive-compulsive disorder with clomipramine. Psychiatr. Ann. (1989) 19:97–101.
   Web of Science ®Google Scholar
• ANANTH J, PECKNOLD JC, VAN DEN STEEN N et al.: Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Frog. Neuropsychopharmacol (1981) 5:257–262.
   Google Scholar
• LNSEL TR, MURPHY DL, COHEN RM et al.: Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch. Gen. Psychiatry. (1983) 40:605–612.
   PubMed Web of Science ®Google Scholar
• PALMER KJ, BENFIELD P: Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs (1994) 1:57–87.
   Web of Science ®Google Scholar
• STAHL SM: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 2nd edn. Cambridge University Press, Cambridge, UK (2000).
   Google Scholar
• GOODMAN WK, WARD H, KABLINGER A et al.: Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J. Clin. Psychiatry (1997) 58(s5):32–49.
   Google Scholar
• NEMEROFF CB, DEVANE CL, POLLOCK GB: Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry (1996) 153:311–320.
   PubMed Web of Science ®Google Scholar
• WRIGHT S, DAWLING S, ASHFORD JJ: Excretion of fluvoxamine in breast milk. Br. J. Clin. PharmacoL (1991) 31:209.
   PubMed Web of Science ®Google Scholar
• BUIST A. NORMAN TR, DENNERSTEIN L: Breast-feeding and the use of psychotropic medication: a review. J. Affect. Disord. (1990) 19:197–206.
   PubMed Web of Science ®Google Scholar
• PRICE LH, GOODMAN WK, CHARNEY DS et al.: Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am. J. Psychiatry (1987)144:1059–1061.
   PubMed Web of Science ®Google Scholar
• MCNAIR D: Original investigations: self evaluations of antidepressants. Psychopharmacology (1974) 37:281.
   PubMedGoogle Scholar
• GUY W: ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76–338. US Department of Health, Education and Welfare, Washington, DC, USA (1976):218–222.
   Google Scholar
• PERSE TL, GREIST JH, JEFFERSON JW et al.: Fluvoxamine treatment of obsessive-compulsive disorder. Am. J. Psychiatry (1987) 144:1543–1548.
   PubMed Web of Science ®Google Scholar
• DEROGATIS LR, RICKELS K, ROCK AF: The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br. J. Psychiatry (1976) 128:280–289.
   PubMed Web of Science ®Google Scholar
• HAMILTON M: A rating scale for depression. J. Neurol Neurosurg. Psychiatry (1960) 23:56–66.
   PubMed Web of Science ®Google Scholar
• MARKS IM, HALLAM RS, PHELLEPOT R et al.: Nursing in Behavioral Psychotherapy: Research Series of the Royal College of Nursing. Royal College of Nursing, London, UK (1977).
   Google Scholar
• GOODMAN WK, PRICE LH, RASMUSSEN SA et al.: Efficacy of fluvoxamine in obsessive-compulsive disorder. Arch. Gen. Psychiatry (1989) 46:36–44.
   PubMed Web of Science ®Google Scholar
• GOODMAN WK, PRICE LH, RASMUSSEN SA et al.: The Yale-Brown Obsessive Compulsive Scale, 1: development, use and reliability. Arch. Gen. Psychiatry (1989) 46:1006–1011.
   PubMed Web of Science ®Google Scholar
• JENIKE MA, HYMAN S, BAER L et al.: A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am. J. Psychiatry (1990) 147:1209–1215.
   PubMed Web of Science ®Google Scholar
• INSEL T, MURPHY D, COHEN R et al: Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch. Gen. Psychiatry (1983) 40:605.
   PubMed Web of Science ®Google Scholar
• GREIST JH, JENIKE MA, ROBINSON D et al.: Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicenter, double-blind, placebo controlled trial. Eur. J. Clin. Res. (1995) 7:195–204.
   Google Scholar
• GOODMAN WK, KOZAK MJ, LIEBOWITZ M et al.: Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre double-blind, placebo-controlled trial. Int. Clin. Psychopharmacd. (1996) 11:21–29.
   PubMed Web of Science ®Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, Revised. American Psychiatric Association, Washington, DC, USA (1987).
   Google Scholar
• HOLLANDER E, KORAN LM, GOODMAN WK et al.: A double-blind, placebo controlled, study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. Clin. Psychiatry (2003) 64:640–647.
   PubMed Web of Science ®Google Scholar
• SMERALDI E, ERZEGOVESI S, BIANCHI I et al.: Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary study. New Trends in Experimental and Clinical Psychiatry (1992) 7:63–65.
   Google Scholar
• FREEMAN CPL, TRIMBLE MR, DEAKIN JFW et al.: Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison./ Clin. Psychiatry (1994) 55:301–305.
   PubMed Web of Science ®Google Scholar
• KORAN LM, MCELROY SL, DAVIDSON JRT et al.: Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J. Clin. Psychopharmacol. (1996) 16:121–129.
   PubMed Web of Science ®Google Scholar
• MILANFRANCHI A, RAVAGLI S, LENSI P et al.: A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (1997) 12:131–136.
   PubMed Web of Science ®Google Scholar
• MUNDO E, BIANCHI L, BELLODI L: Efficacy of fluvoxamine, paroxetine and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. Clin. Psychopharmacol. (1996) 17:267–271.
   Web of Science ®Google Scholar
• MUNDO E, MAINA G, USLENGHI C: Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (2000) 15:69–76.
   PubMed Web of Science ®Google Scholar
• MUNDO E, ROUILLON F, FIGUERA ML et al.: Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum. Psychopharmacol. Clin. Exp. (2001) 16:461–468.
   PubMed Web of Science ®Google Scholar
• HOLLANDER E: Obsessive-Compulsive Related Disorders. American Psychiatric Press, Washington, DC, USA (1993).
   Google Scholar
• PHILLIPS KA, MCELROY SL: An open label study of fluvoxamine in body dysmorphic disorder. Biol. Psychiatry (1996) 39:625.
   Web of Science ®Google Scholar
• PHILLIPS KA, DWIGHT MM, MCELROY SL: Efficacy and safety of fluvoxamine in body dysmorphic disorder. J. Clin. Psychiatry (1998) 59:165–171.
   PubMed Web of Science ®Google Scholar
• HOLLANDER E, COHEN LJ, SIMEON D et al.: Fluvoxamine treatment of body dismorphic disorder. J. Clin. Psychopharmacol. (1994) 14:75–77.
   PubMed Web of Science ®Google Scholar
• HUDSON JI, MCELROY SL, RAYMOND NC et al.: Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am. J. Psychiatry (1998) 155:1756–1762.
   PubMed Web of Science ®Google Scholar
• SCHMIDT U, COOPER PJ, ESSERS H et al.: Fluvoxamine and graded psychotherapy in the treatment of bulimia nervosa: a randomized, double-blind, placebo-controlled, multicenter study of short-term and long-term pharmacotherapy combined with a stepped care approach to psychotherapy. J. Clin. Psychopharmacol. (2004) 24:549–552.
   PubMed Web of Science ®Google Scholar
• MCDOUGLE CJ, NAYLOR ST, COHEN DJ et al.: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch. Gen. Psychiatry (1996) 53:1001–1008.
   PubMed Web of Science ®Google Scholar
• STANLEY MA, BRECKENRIDGE JK, SWANN AC et al.: Fluvoxamine treatment of trichotillomania. J. Clin. Psychopharmacol. (1997) 17:278–283.
   PubMed Web of Science ®Google Scholar
• HOLLANDER E, DECARIA CM, FINKELL JN et al.: A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol. Psychiatry (2000) 47:813–817.
   PubMed Web of Science ®Google Scholar
• BLACK DW, GABEL J, HANSEN J et al.: A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann. Clin. Psychiatry (2000) 12:205–211.
   PubMedGoogle Scholar
• ZOHAR J, KAPLAN Z, BENJAMIN J: Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study. J. Clin. Psychiatry (1994) 55:86–88.
   PubMed Web of Science ®Google Scholar
• PHILLIPS KA, DWIGHT MM, MCELROY SL: Efficacy and safety of fluvoxamine in body dysmorphic disorder. J. Clin. Psychiatry (1998) 59(0165–171.
   PubMed Web of Science ®Google Scholar
• CHONG SA, LOW BL: Treatment of kleptomania with fluvoxamine. Acta Psychiatr. Scand. (1996) 9 3(0314–3 1 5.
   Google Scholar
• BLANCO C, PETKOVA E, IBANEZ A et al.: A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann. Clin Psychiatry (2002) 14:9–15.
   PubMedGoogle Scholar
• MCDOUGLE CJ, GOODMAN WK, LECKMAN JF et al.: Haloperidol addition in fluvoxamine refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry (1994) 1:301–308.
   Google Scholar
• MCDOUGLE CJ, GOODMAN WK, PRICE LH et al.: Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder: an open case series. Am. J. Psychiatry (1990) 147:652–654.
   PubMed Web of Science ®Google Scholar
• DELGADO PL, GOODMAN WK, PRICE LH et al.: Fluvoxamine/pimozide treatment of concurrent treatment Tourette's and obsessive-compulsive disorder. Br. J. Psychiatry (1990) 157:762–765.
   PubMed Web of Science ®Google Scholar
• GEORGE MS, TRIMBLE MR, ROBERTSON MM: Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome. Hum. Psychopharmacol. (1993) 8:327–334.
   Web of Science ®Google Scholar
• ERZEGOVESI E, GUGLIELMO E, SILIPRANDI F et al.: Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind placebo controlled study. Eur. Neuropsychopharmacol. (2005) 15:69–74.
   PubMed Web of Science ®Google Scholar
• BOGETTO F, BELLINO, VASCHETTO et al.: Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. (2000) 96:91–98.
   PubMed Web of Science ®Google Scholar
• WAGNER W, ZABORNY BA, GRAY TE: Fluvoxamine: a review of its safety profile in world-wide studies. Int. J. Psychopharmacol. (1995) 9:223–227.
   Web of Science ®Google Scholar
• MAINA G, ALBERT U, SALVI V, BOGETTO F: Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J. Clin. Psychiatry. (2004) 65(10):1365–1371.
   PubMed Web of Science ®Google Scholar
• DE HAAN E, VAN OPPEN P, VAN BALKOM AJLM et al.: Prediction of outcome and early versus late improvement in OCD patients treated with cognitive behavior therapy and pharmacotherapy. Acta Psychiatr. Scand. (1997) 96:354–361.
   Google Scholar
• MONTGOMERY SA: Long-term management of obsessive-compulsive disorder. Int. Clin. Psychopharmacol. (1996) 11(s5):23–29.
   Google Scholar
• PATO MT, ZOHAR-KADOUCH R, ZOHAR J et al.: Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am. J. Psychiatry (1988) 145:1521–1525.
   PubMed Web of Science ®Google Scholar
• LEONARD HL, SWEDO SE, LENANE MC et al.: A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch. Gen. Psychiatry (1991) 48:922–927.
   PubMed Web of Science ®Google Scholar
• STEINER M, BUSHNELL W, GERGEL I et al.: Long-term treatment and prevention of relapse of OCD with paroxetine. In: New Research program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association. Miami, FL, USA (20 — 25 May 1995) NR 354:150.
   Google Scholar
• RAVIZZA L, BARZEGA G, BELLINO S et al.: Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors. Psychopharmacol Bull. (1996) 32:167–173.
   PubMed Web of Science ®Google Scholar
• MALLYA GK, WHITE K, WATERNAUX G et al.: Short- and long-term treatment of obsessive-compulsive disorder with fluvoxamine. Ann. Clin. Psychiatry (1988) 145:1521–1525.
   Google Scholar
• FLEISHAKER JC, HULST LK: A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur. J. Clin. Pharmacol (1994) 46:35–39.
   PubMed Web of Science ®Google Scholar
• DEQUARDO JR, ROBERTS M: Elevated clozapine levels after fluvoxamine initiation. Am. J. Psychiatry (1996) 153:840–841.
   PubMed Web of Science ®Google Scholar
• HARTTER S, ARAND M, DESCH F et al.: Non-competitive inhibition of clomipramine N-demethylation of fluvoxamine. Psychopharmacology (1995) 117:149-153. Affiliation Bernardo Dell'Osso MD, Andrea Allen PhD 8c Eric Hollandert MD tAuthor for correspondence Compulsive, Impulsive and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1230, New York, NY 10029, USA Tel: +1 212 241 3623; Fax: +1 212 987 4031; E-mail: [email protected]
   Google Scholar